zilucoplan
Phase 3- Indications
- Generalized myasthenia gravis, Immune-mediated necrotizing myopathy, Amyotrophic lateral sclerosis
Company intelligence / Profile preview
Ra Pharmaceuticals
Cambridge, Massachusetts, USArapharmaceutical.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 3
01
Overview
Ra Pharmaceuticals developed synthetic macrocyclic peptide drugs targeting the complement system. Its lead asset, zilucoplan—a subcutaneous C5 inhibitor—completed Phase II trials for gMG and PNH and entered Phase III for gMG before the company was acquired by UCB in April 2020. Preclinical programs targeted additional complement-related indications. Zilucoplan showed promise as a once-daily self-administered therapy with potential applications across several rare autoimmune disorders.[2][4]
- Therapeutic areas
- HematologyImmunologyNeurologyNephrology
- Modalities
- Synthetic macrocyclic peptidesPeptide inhibitors[2][4][7]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major disclosed partnerships outside parent company at time of acquisition.
Beyond the preview
Go deeper on Ra Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ra Pharmaceuticals.